PTPRC and acute myeloid leukemia: In contrast to marked suppression of AML in vivo (Fig. 5), immunohistological staining of engrafted donor CD34 + cells in sternal bone marrow (Fig. 6a and Suppl Fig. 3) and flow cytometric enumeration of flushed femurs (Fig. 6b) showed minimal impact of combined S55746/S63845 treatment on normal CD45 + cells.